• español
    • English
  • Login
  • español 
    • español
    • English

UniversidaddeCádiz

Área de Biblioteca, Archivo y Publicaciones
Comunidades y colecciones
Ver ítem 
  •   RODIN Principal
  • Producción Científica
  • Artículos Científicos
  • Ver ítem
  •   RODIN Principal
  • Producción Científica
  • Artículos Científicos
  • Ver ítem
JavaScript is disabled for your browser. Some features of this site may not work without it.

Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies

Thumbnail
Identificadores

URI: http://hdl.handle.net/10498/25734

DOI: 10.3390/biom11081072

ISSN: 2218-273X

Ficheros
2021_678.pdf (406.3Kb)
Estadísticas
Ver estadísticas
Métricas y Citas
 
Compartir
Exportar a
Exportar a MendeleyRefworksEndNoteBibTexRIS
Metadatos
Mostrar el registro completo del ítem
Autor/es
Cid, Raquel; Bolívar Pérez, JorgeAutoridad UCA
Fecha
2021-08
Departamento/s
Biomedicina, Biotecnología y Salud Pública
Fuente
Biomolecules 2021, 11(8), 1072
Resumen
To date, vaccination has become one of the most effective strategies to control and reduce infectious diseases, preventing millions of deaths worldwide. The earliest vaccines were developed as live-attenuated or inactivated pathogens, and, although they still represent the most extended human vaccine types, they also face some issues, such as the potential to revert to a pathogenic form of live-attenuated formulations or the weaker immune response associated with inactivated vaccines. Advances in genetic engineering have enabled improvements in vaccine design and strategies, such as recombinant subunit vaccines, have emerged, expanding the number of diseases that can be prevented. Moreover, antigen display systems such as VLPs or those designed by nanotechnology have improved the efficacy of subunit vaccines. Platforms for the production of recombinant vaccines have also evolved from the first hosts, Escherichia coli and Saccharomyces cerevisiae, to insect or mammalian cells. Traditional bacterial and yeast systems have been improved by engineering and new systems based on plants or insect larvae have emerged as alternative, low-cost platforms. Vaccine development is still time-consuming and costly, and alternative systems that can offer cost-effective and faster processes are demanding to address infectious diseases that still do not have a treatment and to face possible future pandemics.
Materias
vaccine; protein expression system; alternative platform; subunit; recombinant antigen
Colecciones
  • Artículos Científicos [12014]
  • Articulos Científicos Biomedicina [582]
  • Artículos Científicos INBIO [422]
Atribución 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional

Listar

Todo RODINComunidades y ColeccionesPor fecha de publicaciónAutoresTítulosMateriasEsta colecciónPor fecha de publicaciónAutoresTítulosMaterias

Mi cuenta

AccederRegistro

Estadísticas

Ver Estadísticas de uso

Información adicional

Acerca de...Deposita en RODINPolíticasNormativasDerechos de autorEnlaces de interésEstadísticasNovedadesPreguntas frecuentes

RODIN está accesible a través de

OpenAIREOAIsterRecolectaHispanaEuropeanaBaseDARTOATDGoogle Académico

Enlaces de interés

Sherpa/RomeoDulcineaROAROpenDOARCreative CommonsORCID

RODIN está gestionado por el Área de Biblioteca, Archivo y Publicaciones de la Universidad de Cádiz

ContactoSugerenciasAtención al Usuario